FDA Approves Merilog, First Rapid-Acting Insulin Biosimilar for Patients With Diabetes
By Stephanie Brown HealthDay Reporter
WEDNESDAY, Feb. 19, 2025 -- The U.S. Food and Drug Administration has approved Merilog (insulin-aspart-szjj) as a biosimilar to Novolog (insulin aspart) for adults and pediatric patients with diabetes mellitus.
Merilog is a rapid-acting human insulin analog and the first rapid-acting insulin biosimilar product approved by the FDA. Administering Merilog subcutaneously five to 10 minutes before mealtime helps improve glycemic control in patients with diabetes. Both a 3-mL single-patient-use prefilled pen and a 10-mL multiple-dose vial are included in this approval.
Serious side effects reported with Merilog include hypoglycemia, severe allergic reactions, and low potassium levels in the blood. Common side effects include injection site reactions, itching, rash, skin thickening or pitting at the injection site, weight gain, and swelling of hands and feet.
"The FDA has now approved three biosimilar insulin products to treat diabetes," Peter Stein, M.D., director of the Office of New Drugs in the FDA Center for Drug Evaluation and Research, said in an agency press release. "Today’s approval highlights our continued efforts to improve the efficiency of the biosimilar approval process to help support a competitive marketplace and increase options for costly treatments, like insulin. Increasing access to safe, effective and high-quality medications at potentially lower cost remains a continued priority for the FDA."
Approval of Merilog was granted to Sanofi-Aventis.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted February 2025
Read this next
Combo Diabetes/High Blood Pressure Threatening More American Lives
FRIDAY, May 30, 2025 — Twice as many Americans now face the increased risk of death that comes from having both high blood pressure and type 2 diabetes, a new study...
Preschool BMI Can Predict Childhood Obesity Risk
WEDNESDAY, May 28, 2025 — Preschoolers who don’t naturally lose weight are more likely to develop full-fledged childhood obesity by age 9, a new study says. Most kids...
FDA Halts Sale of Off-Brand Ozempic and Other GLP-1 Drugs
FRIDAY, May 23, 2025 — A federal deadline ending sale of off-brand weight-loss and diabetes medications is now in effect, cutting off access to drugs many patients count...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.